Figure 5 from Clinically Relevant Humanized Mouse Models of Metastatic Prostate Cancer Facilitate Therapeutic Evaluation

Myeloid-support exhibits immuno-dampened profile in huNOG-EXL 22Rv1 xenograft tumors. A, Gating strategy used to determine presence of human CD45⁺ cells in the NOG-EXL model. B, Representative data showing the abundance of various immune cell populations; human leukocytes, CD19⁺ cells, CD3⁺ cells, and double negative cells; MDSC and activated myeloid cells; and helper T cells (CD4⁺) and cytotoxic T cells (CD8⁺; top to bottom). C, Quantitated data comparing human CD45, CD3, CD4, and CD11b populations in tumors isolated from testosterone-implanted vehicle, intact vehicle, castrated vehicle, and castrated enzalutamide treated mice. D, Gating strategy for determining the activation state of MDSCs (CD3⁻ CD19⁻ CD11b⁺ CD14⁻). E, Representative data showing the activation state of the MDSC cells harvested from tumors under different treatment categories through the presence of the surface markers: CD25, CD44, CD69, and PD-1. F, Quantitated data showing the activation state of the MDSCs throughout the different treatments.